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A B S T R A C T
Purpose
The Ewing sarcoma family of tumors (ESFT) is a group of malignant tumors of soft tissue and bone
sharing a chromosomal translocation affecting the EWS locus. The Intergroup INT-0091 demon-
strated the superiority of a regimen of vincristine, cyclophosphamide, doxorubicin (VDC), and
dactinomycin alternating with ifosfamide and etoposide (IE) over VDC for patients with nonmeta-
static ESFT of bone. The goal of this study was to determine whether a dose-intensified regimen
of VDC alternating with IE would further improve the outcome for patients with nonmetastatic
ESFT of bone or soft tissue.
Methods
Patients with previously untreated, nonmetastatic ESFT of bone or soft tissue were eligible. They
were randomly assigned to receive standard doses of VDC/IE over 48 weeks or a dose-intensified
regimen of VDC/IE over 30 weeks.
Results
Four hundred seventy-eight patients met eligibility requirements: 231 patients received the
standard regimen; 247 patients received the intensified regimen. The 5-year event-free survival
(EFS) and overall survival rates for all eligible patients were 71.1% (95% CI, 67.7% to 75.0%) and
78.6% (95% CI, 74.6% to 82.1%), respectively. There was no significant difference (P  .57) in
EFS between patients treated with the standard (5-year EFS, 72.1%; 95% CI, 65.8% to 77.5%) or
intensified regimen (5-year EFS, 70.1%; 63.9% to 75%). Patients with soft tissue tumors
accounted for 20% of the study population; there was no difference in outcome between patients
with soft tissue and bone primary sites.
Conclusion
Dose escalation of alkylating agents as tested in this trial did not improve the outcome for patients
with nonmetastatic ESFT of bone or soft tissue.
J Clin Oncol 27:2536-2541. © 2009 by American Society of Clinical Oncology
INTRODUCTION
The Ewing sarcoma family of tumors (ESFT) con-
sists of Ewing sarcoma and primitive neuroectoder-
mal tumors (PNET) of bone and soft tissue. These
tumors share the presence of a translocation t(11;22)
or one of its variants.1 The use of multimodality
therapy dramatically improved the outcome for
these patients from 15% to 20% with surgery and/or
radiation2,3 to 60% to 70%.4-6
Intergroup study INT-0091 demonstrated that
the addition of ifosfamide and etoposide (IE) to
vincristine, doxorubicin, and cyclophosphamide
(VDC) resulted in a significant improvement in
event-free survival (EFS) and overall survival (OS)
for patients with nonmetastatic ESFT of bone.7 Pa-
tients treated with the experimental arm had a
5-year OS rate of 72%, as compared with 61%
for patients treated with the standard regimen
(P  .01).
The earlier Intergroup Study (IESS-II) demon-
strated improved survival for patients with nonpel-
vic disease treated with a high-dose intermittent
regimen (5-year disease-free survival rate, 68%)
compared with the less intense regimen (5-year
disease-free survival rate, 48%.)8 Although Smith et
al9,10 attributed this difference to the dose-intensity
of doxorubicin, these regimens also differed in the
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total doses of alkylating agents. The goal of this study was to determine
whether a dose-intensified regimen of VDC and IE would further
improve the outcome for these patients.
Dose intensification is defined as the amount of drug over unit
time.11 One may dose intensify therapy by keeping the interval stable
while escalating the dose(s) of the chemotherapeutic agents, or one
can shorten the interval between cycles. Because ESFT are exquisitely
sensitive to alkylating agents,12,13 and hematopoietic growth factors
allow for dose intensification, the investigational regimen of this study
used dose-intensified alkylating agents yet kept the cumulative doses
of the drugs similar between the two arms.
Previous clinical trials of ESFT limited eligibility to patients with
bone primaries. There is a subset of soft tissue tumors histologically
identical to ESFT that share the same chromosomal translocation.14 A
secondary objective of this study was to determine the incidence of
primary bone versus soft tissue tumors and to determine whether the
prognosis differed by soft tissue or bone site. Additional goals were to
determine the impact of histologic subtype on prognosis, the inci-
dence of serious toxicities by regimen, and to estimate the occurrence
of second malignant neoplasms (SMNs). This article reports the re-
sults of this study.
METHODS
Patients
National Cancer Institute protocol INT-0154 (Children’s Cancer Group
7942/Pediatric Oncology Group 9354) was opened to all member institutions
of the Children’s Cancer Group and the Pediatric Oncology Group between
May 1995 and September 1998. Eligible patients were younger than 30 years at
enrollment and had ESFT of bone or soft tissue excluding the brain and no
metastases identified before enrollment. ESFTs were eligible on the basis of a
light microscopic appearance of a small round-cell neoplasm consistent with
Ewing sarcoma or PNET. The following immunohistochemical studies were
required: desmin or muscle-specific actin, leukocyte common antigen, and
MIC2 antibody (12E7 or HBA 71). Patients without immunohistochemical or
ultrastructural evidence excluding Ewing sarcoma or PNET were eligible.
Patients with immunohistochemical evidence supporting a diagnosis of rhab-
domyosarcoma were ineligible. All pathology specimens underwent central
review. Eligibility requirements included normal liver, renal, and cardiac func-
tion. Patients must have started protocol therapy within 30 days of diagnostic
biopsy and not have had any systemic anticancer therapy before study entry.
All patients/guardians gave written informed consent according to institu-
tional and National Cancer Institute guidelines, and the protocol was ap-
proved by the institutional review boards at all participating centers.
Study Design
Patients were randomly assigned to standard or intensified therapy (Fig
1). Chemotherapy courses were VDC alternating with IE delivered every 3
weeks (Fig 1). The standard regimen prescribed 17 cycles of chemotherapy
administered over 48 weeks; the intensified regimen prescribed 11 cycles given
over 30 weeks. Granulocyte colony-stimulating factor support for both regi-
mens (5 g/kg/d) was prescribed. The total doses of all agents were similar (Fig
1). The intent was to deliver similar cumulative doses of the agents to deter-
mine the effect of early dose intensification without a change in total chemo-
therapeutic drug exposure.
Local control was performed after week 12 and consisted of resection or
radiotherapy. Patients who had close or positive margins received postresec-
tion radiotherapy. Patients were eligible for study if a resection had been done
before study entry; if these patients did not have a prechemotherapy complete
resection, it was the treating physician’s option to give radiation or perform a
repeat resection after week 12 of therapy. Patients who were treated with
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Fig 1. Treatment schema with cumula-
tive doses of agents by regimen.
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radiation therapy only after week 12 could receive delayed surgical resection
after week 30. Patients with bone primaries who received radiation therapy as
primary therapy, and those with gross residual disease after surgery, received a
dose of 45 Gy to the initial tumor volume (plus 2-cm margin) with a boost of
10.8 Gy, for a total dose of 55.8 Gy to the post–neoadjuvant therapy tumor
volume. For patients with extraosseous tumor who had a complete response to
induction chemotherapy, the initial tumor volume plus a 2-cm margin re-
ceived 45 Gy followed by a boost of 5.4 Gy with a 1-cm margin, to a total dose
of 50.4 Gy. Patients with postoperative microscopic residual or close margins,
defined as less than 1 cm for bone, less than 5 mm for fat and muscle, and less
than 2 mm for facial planes, received 45 Gy to the primary initial volume plus
2-cm margin followed by a boost to the site of close or positive margins, to a
total dose of 50.4 Gy. No radiation was recommended for patients with
complete tumor resection before or at the local control time point, regardless
of the extent of necrosis or size of the original tumor.
Statistical Analysis
The study was designed to accrue 423 eligible patients. The primary end
point for the estimation of relative efficacy was EFS. Risk of adverse event was
compared between regimens using a log-rank test. The sample size allowed
detection of a 1.5-fold decrease in failure rate, with probability of 0.80 when
using a two-sided test of size 5%. The expected accrual duration was 4.7 years
with 3 years of follow-up after the last patient was entered. Data and follow-up
received through December 2006 were included in the analysis data set. EFS
was defined as the time from study entry until the occurrence of an analytic
event or date of last patient contact, whichever came first. An analytic event
was defined as disease progression, diagnosis of SMN, or death before the
development of disease progression or SMN. OS was defined as the time from
study entry until the death or date of last patient contact, whichever came first.
Death, regardless of cause, was considered an event.
EFS and OS were estimated by the method of Kaplan and Meier.15 Risk of
adverse event was compared across groups defined by treatment or prognostic
factors using the log-rank test. Comparisons involving the chemotherapy
randomization were conducted with patients’ outcomes assigned to the treat-
ment arm to which they were randomly assigned at enrollment. The prognos-
tic significance and associated relative risk for various patient characteristics
measured at study entry were assessed by a proportional hazards regression
model with the characteristic of interest as the only component.16 CIs for
relative risks were derived from the proportional hazards regression model.
Interim monitoring was conducted 30 and 42 months after the study was
opened. A P value of less than .001 was used as the monitoring boundary for all
interim analyses.
EFS events were further classified into six modes: (1) disease progression
or recurrence at the initial site of disease (local recurrence), (2) disease pro-
gression or recurrence at a site not initially involved by disease (distant recur-
rence), (3) disease progression or recurrence at the initial site of disease as well
as at least one site not initially involved by disease (local plus distant recur-
rence), (4) disease progression or recurrence, but not enough details were
supplied to determine the exact sites of progression (disease recurrence–
undetermined site), (5) diagnosis of an SMN, and (6) death without an
intervening disease- or SMN-related event. The cumulative incidence of each
failure mode was calculated by the method as described by Gray.17 For each
event type, the equality of risk for each such event type was tested using the
relative risk regression model, with the other events that defined the outcome
considered as censoring events.16 Possible heterogeneity in risk for EFS event
was examined using a relative risk regression model that included terms for site
of bone primary, randomized treatment, and interaction terms for site and
treatment. The hypothesis of no interaction terms was tested using the differ-
ence in partial likelihoods for the models including and excluding the interac-
tion terms.
Toxicity was graded according to the Pediatric Oncology Group/
Children’s Cancer Group toxicity criteria (schedule of toxicities available on
request from Children’s Oncology Group). Each patient was classified accord-
ing to the maximum grade of toxicity experienced at any time during protocol
therapy for each of the 37 categories evaluated.
RESULTS
Patient Characteristics
Of the 492 patients enrolled, 478 patients with nonmetastatic
ESFT were eligible. Thirteen patients were ineligible (13 patients had
incorrect diagnosis and one patient had lung metastases). The incor-
rect diagnosis included rhabdomyosarcoma (n  3), undifferentiated
sarcoma (n  1), neuroblastoma (n  2), and other tumors (n  7).
Characteristics at time of diagnosis for patients enrolled onto the study
are listed in Table 1. Two hundred sixty-three patients (55%) were
male; 401 patients (84%) were white and 18 patients (4%) were Afri-
can American, reflecting the rarity of ESFT among people of African
ethnicity. Ninety-four patients (20%) had soft tissue tumors, 377
patients (80%) had bone primaries, and seven patients had insuffi-
cient data to classify site. Among patients with bone tumors, 70 pa-
tients (19%) had pelvic, 175 patients (46%) had appendicular, and 75
patients (20%) had thoracic tumors.
Outcome
Of 478 eligible patients, 119 patients experienced disease progres-
sion, 18 patients developed SMNs, and 14 patients died as their first
event. Patients who did not experience an EFS event were followed for
a median of 8.3 years. The EFS rate for all patients was 71.1% (95% CI,
66.7% to 75.0%) at 5 years. The OS rate was 78.6% (95% CI, 74.6% to
82.1%) at 5 years. There was no significant difference in risk for EFS
event or death when the standard and intensified regimens are com-
pared (Fig 2; Appendix Fig A1, online only). The 5-year EFS rate for
the standard regimen is 72.1% (95% CI, 65.8% to 77.5%), and the
5-year EFS rate for the intensified regimen is 70.1% (95% CI, 63.9% to
75.5%). Similarly, there was no difference in OS between the two
regimens (5-year OS for the standard regimen, 80.5% [95% CI, 74.7%
to 85.1%], and for the intensified regimen, 77.0% [95% CI, 71.1% to
81.8%]). Patients with pelvic primary tumors had an EFS and OS
similar to that of patients with other primary tumors of bone (Fig 3;
P  .57). Outcome did not differ significantly between bone and soft
tissue primary tumors: 5-year EFS, 71.3% (95% CI, 66.4% to 75.6%)
versus 70.2% (95% CI, 59.6% to 78.5%; P  .78), respectively (Ap-
pendix Fig A2, online only). Overall 5-year EFS by age group at
enrollment (1 to 9 years, 77.5% [95% CI, 69.8% to 83.4%], v 10 to 17
years, 69.4% [95% CI, 63.4% to 74.7%] v 18 years, 63.2% [95% CI,
49.9% to 73.8%]) yielded a P value of .018 (trend), with the younger
patients having better outcome (Appendix Fig A3, online only).
Local Control
Of the 478 eligible patients, 77 patients were excluded from the
analysis of local control. Three patients experienced an analytic event
before the completion of induction chemotherapy. Data was insuffi-
cient to determine the local control for the remaining excluded pa-
tients. One patient with a femur tumor was reported not to have any
local control; this individual is excluded from the subsequent analysis.
Among the remaining 400 patients, the local control method used did
not significantly differ between the two regimens (Appendix Table A1,
online only).
Patterns of Failure
The cumulative incidences of the various types of events were not
statistically different when the two regimens were compared (Table 2).
Of the 55 disease recurrences in patients enrolled onto the standard
Granowetter et al
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regimen, 15 were local, 32 were distant, and six had both local plus
distant components; the site of recurrence was not reported in two
cases. Of the 64 disease recurrences in patients enrolled onto the
intensified regimen, 13 were local, 34 were distant, and 15 had both
local plus distant components; the site of recurrence was not reported
in two cases. Eighteen SMNs were reported; seven among patients
receiving the standard regimen and 11 among patients receiving the
intensified regimen. Eight patients on the standard and six on the
intensified regimen died before any EFS event.
Local control with radiation therapy only was associated with a
significantly increased risk for failure at local and distant sites (Table
3). No other significant differences in pattern of failure as it related to
local control modality were noted.
SMNs
There were 12 patients with secondary leukemia and seven pa-
tients with secondary solid tumors (Appendix Tables A2 and A3,
online only). Among the patients with leukemia, nine patients had
cytogenetic data available; all had cytogenetics consistent with second-
ary leukemia: seven 11q23 abnormalities, one del(7). Seven patients
with secondary leukemia were treated with standard and five with
Table 1. Patient Characteristics
Characteristic
Standard (n  231) Intensified (n  247) Overall (N  478)
No. % No. % No. %
Sex
Male 127 55 136 55 263 55
Female 104 45 111 45 215 45
Age at diagnosis, years
1-9 71 31 77 31 148 31
10-17 121 52 144 58 265 55
18 39 17 26 11 65 14
Race/ethnicity
White 190 82 211 85 401 84
African American 11 5 7 3 18 4
Asian 20 9 24 10 44 9
Other 10 4 5 2 15 3
Primary tumor site
Bone 177 78 200 82 377 80
Soft tissue 50 22 44 18 94 20
Not reported 4 3 7
Primary site, bone lesions
Pelvis 30 17 40 20 70 19
Thoracic 30 23 35 18 75 20
Other axial 27 15 30 15 57 15
Appendicular 80 45 95 48 175 46






























































Fig 3. Overall survival for all eligible patients by primary bone site.
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intensified therapy. Six of the seven patients with secondary solid
tumors were treated on the intensified regimen. Of these, three pa-
tients had radiation to the site of the second malignancy. One patient
with secondary osteosarcoma never received radiation. The one pa-
tient randomly assigned to the standard regimen who developed a
solid tumor never received radiation therapy; this patient developed
renal cell carcinoma 3 years after disease progression of Ewing
sarcoma.
Toxicity
The following grade 3 and 4 toxicities were reported more fre-
quently among patients treated on the investigational regimen: neu-
tropenia, thrombocytopenia, anemia, diarrhea, stomatitis, Fanconi
syndrome (primarily grade 3), fungal stomatitis, hematuria, sepsis,
and infection. Appendix Table A4 (online only) gives the comparison
of selected grade 3 or worse toxicities by treatment regimen.
DISCUSSION
Dose intensification as studied in this clinical trial did not result in an
improved outcome for patients with nonmetastatic ESFT. The dose of
cyclophosphamide during the 12-week induction on the investiga-
tional arm was 350% greater than the cyclophosphamide dose on the
standard arm; during weeks 13 to 30 on the investigational arm and
weeks 13 to 48 on the standard arm, the dose-intensity for cyclophos-
phamide was the same. The ifosfamide dose was 133% greater
throughout the 30 weeks of the investigational regimen compared
with the standard regimen. Thus despite significant intensification of
both early cyclophosphamide and ifosfamide dose, we could not dem-
onstrate improved survival for patients on the investigational therapy.
This is similar to the failure of chemotherapy dose intensification to
improve survival in patients for metastatic ESFT. Unexpectedly, pa-
tients with pelvic tumors did not have an inferior survival as compared
with that of patients with primary tumors at other sites. This is a new
finding and did not differ between the regimens.18 The percentage
(19%) of patients with bone primary with pelvic tumors is slightly
lower than that of other published series (23% to 25%)6,7 but did not
differ between regimens and thus would not impact comparison be-
tween the regimens.
The majority of patients on this study were treated with surgery
alone for local therapy. European groups have advocated the use of
surgery followed by radiation in patients with large tumors and those
with a poor pathologic response to chemotherapy as ascertained at the
time of surgical local control. In contrast, we used radiation therapy
after surgery only in patients with close or positive margins after
resection. There is no evidence that our patients with large tumors
would have derived a benefit from adding radiation therapy, as local
control rates are comparable to those reported in European studies.6
An analysis of the chest wall tumors treated on this study and INT-
0091 demonstrated that there was no benefit to the addition of radia-
tion to the treatment of patients with chest wall tumors with negative
margins after resection.19
There was no difference between the two regimens in regard to
the incidence of secondary leukemia. The incidence of secondary
leukemia and solid tumors among patients on this study is similar to
that reported for patients treated on INT-0091 and other contempo-
rary series. One study did report a higher incidence of secondary
leukemia; the highly intensified Regimen C in INT-009120,21 for pa-
tients with metastatic Ewing sarcoma of bone found a cumulative
incidence of secondary leukemia or myelodysplasia of 11% at 5 years.
That protocol differs from the experimental arm of this study in that
patients were exposed to twice the cumulative dose of alkylating agents
and had a higher dose rate and cumulative dose of doxorubicin. Thus
the excess incidence of leukemia and myelodysplasia on INT-0091
Regimen C for patients with metastatic disease was probably related to
the cumulative agent exposure and/or dose rate of doxorubicin rather
than dose intensification of alkalating agents alone.
The incidence of solid tumors among the INT-0154 patients
reported here is small. The incidence of secondary solid tumors in-
creases over time, thus it may be too soon to obtain an accurate
estimate of the incidence of secondary solid tumors.22 Most reports of
secondary solid tumors report a strong association with radiation and






Local recurrence 6.2 5.4 .60
Distant recurrence 12.9 13.3 .97
Local plus distant recurrence 2.2 6.2 .072
Indeterminant site of recurrence 0.9 0.8 .95
Second malignant neoplasm 3.1 2.1 .41
Death without other EFS event 2.6 2.1 .52
Abbreviation: EFS, event-free survival.
Table 3. Cumulative Incidences of Specific Event Types After Local Control According to Local Control Modality Used
Event Type
5-Year Cumulative Incidence (%)
PSurgery Only Radiation Therapy Only Surgery Plus Radiation Therapy
Local recurrence 5.1 9.2 2.0 .16
Distant recurrence 11.8 13.9 15.8 .62
Local plus distant recurrence 2.7 8.0 5.9 .038
Indeterminant site of recurrence 0 0 2 —
Second malignant neoplasm 2.8 3.5 2.0 .30
Death without other EFS event 2.4 2.3 0 .99
Abbreviation: EFS, event-free survival.
Only one event occurred. The P value could not be calculated.
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alkylating agent exposure.22,23 We note that half of the patients who
developed a secondary solid tumor did not receive radiation to the site
of the secondary malignancy.
There was no difference in EFS and OS between ESFT patients
with extraosseous and those with bone primary tumors. This is con-
sistent with a recent report from France24 describing the treatment of
EOE and bone primary ESFT patients on the same protocol, as com-
pared with previous protocols, during which EOE patients received
treatment on malignant mesenchymal tumor trials.
In conclusion, dose intensification of alkylating agents as tested
here did not improve OS and EFS for patients with ESFT. Twenty
percent of patients had soft tissue tumors and outcome for those
patients was the same as those with ESFT of bone. The incidence of
secondary leukemia did not differ between the regimens. Secondary
solid tumors were more frequent among patients on the investiga-
tional regimen, and half of these tumors were not associated with
radiation therapy.
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